Bradykinin antagonists modified with dipeptide mimetic beta-turn inducers

Bioorganic & Medicinal Chemistry Letters
Maria C AlcaroAnna Maria Papini

Abstract

Bradykinin (BK) is involved in a wide variety of pathophysiological processes. Potent BK peptide antagonists can be developed introducing constrained unnatural amino acids, necessary to force the secondary structure of the molecule. In this paper, we report a structure-activity relationship study of two peptide analogues of the potent B2 antagonist HOE 140 by replacing the D-Tic-Oic dipeptide with conformationally constrained dipeptide mimetic beta-turn inducers.

References

Mar 1, 1991·British Journal of Pharmacology·F J HockJ Knolle
Feb 1, 1991·British Journal of Pharmacology·F LembeckJ Knolle
Jun 1, 1996·Immunopharmacology·J M StewartE T Whalley
Nov 21, 1997·Journal of Molecular Biology·P GüntertK Wüthrich
Feb 13, 1999·Journal of Medicinal Chemistry·C GaloppiniP Rovero
Nov 8, 2001·European Journal of Pharmacology·R CoutureF Cloutier
May 25, 2002·Canadian Journal of Physiology and Pharmacology·Stefania MeiniCarlo Alberto Maggi

❮ Previous
Next ❯

Citations

Oct 4, 2016·Journal of Medicinal Chemistry·Olivier Van der PoortenDirk Tourwé
Feb 3, 2007·Journal of Peptide Science : an Official Publication of the European Peptide Society·S BalletD Tourwé
Nov 7, 2019·The Journal of Organic Chemistry·Massimo SerraLino Colombo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.